Synthesis and Validation of a Hydroxypyrone-Based, Potent, and Specific Matrix Metalloproteinase-12 Inhibitor with Anti-Inflammatory Activity In Vitro and In Vivo

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2015 Sep 10

PMID 26351407

Citations 6

Authors

J Aerts

R E Vandenbroucke

R Dera

S Balusu

E Van Wonterghem

L Moons

C Libert

W Dehaen

L Arckens

Affiliations

Soon will be listed here.

Abstract

A hydroxypyrone-based matrix metalloproteinase (MMP) inhibitor was synthesized and assayed for its inhibitory capacity towards a panel of ten different MMPs. The compound exhibited selective inhibition towards MMP-12. The effects of inhibition of MMP-12 on endotoxemia and inflammation-induced blood-cerebrospinal fluid barrier (BCSFB) disruption were assessed both in vitro and in vivo. Similar to MMP-12 deficient mice, inhibitor-treated mice displayed significantly lower lipopolysaccharide- (LPS-) induced lethality compared to vehicle treated controls. Following LPS injection Mmp-12 mRNA expression was massively upregulated in choroid plexus tissue and a concomitant increase in BCSFB permeability was observed, which was restricted in inhibitor-treated mice. Moreover, an LPS-induced decrease in tight junction permeability of primary choroid plexus epithelial cells was attenuated by inhibitor application in vitro. Taken together, this hydroxypyrone-based inhibitor is selective towards MMP-12 and displays anti-inflammatory activity in vitro and in vivo.

Citing Articles

In Vitro Models of the Blood-Cerebrospinal Fluid Barrier and Their Applications in the Development and Research of (Neuro)Pharmaceuticals.

Dabbagh F, Schroten H, Schwerk C Pharmaceutics. 2022; 14(8).

PMID: 36015358 PMC: 9412499. DOI: 10.3390/pharmaceutics14081729.

Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Local Tissue Damage Induced by a Type P-I Snake Venom Metalloproteinase.

Preciado L, Pereanez J, Comer J Toxins (Basel). 2019; 12(1).

PMID: 31861940 PMC: 7020480. DOI: 10.3390/toxins12010008.

Adamantyl pyran-4-one derivatives and their in vitro antiproliferative activity.

Petrovic Perokovic V, Car Z, Usenik A, Opacak-Bernardi T, Juric A, Tomic S Mol Divers. 2019; 24(1):253-263.

PMID: 30953295 DOI: 10.1007/s11030-019-09948-1.

A Hydroxypyrone-Based Inhibitor of Metalloproteinase-12 Displays Neuroprotective Properties in Both and Optic Nerve Crush Animal Models.

Vinet J, Costa A, Salinas-Navarro M, Leo G, Moons L, Arckens L Int J Mol Sci. 2018; 19(8).

PMID: 30044455 PMC: 6121268. DOI: 10.3390/ijms19082178.

Brain Barrier Breakdown as a Cause and Consequence of Neuroinflammation in Sepsis.

Danielski L, Giustina A, Badawy M, Barichello T, Quevedo J, Dal-Pizzol F Mol Neurobiol. 2017; 55(2):1045-1053.

PMID: 28092082 DOI: 10.1007/s12035-016-0356-7.

References

Liu Z, Piyamongkol S, Liu D, Khodr H, Lu S, Hider R . Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. Bioorg Med Chem. 2001; 9(3):563-73. DOI: 10.1016/s0968-0896(00)00273-x. View

Johnson L, Pavlovsky A, Johnson A, Janowicz J, Man C, Ortwine D . A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition. J Biol Chem. 2001; 275(15):11026-33. DOI: 10.1074/jbc.275.15.11026. View

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

Puerta D, Mongan J, Tran B, McCammon J, Cohen S . Potent, selective pyrone-based inhibitors of stromelysin-1. J Am Chem Soc. 2005; 127(41):14148-9. DOI: 10.1021/ja054558o. View

Sonneville R, Verdonk F, Rauturier C, Klein I, Wolff M, Annane D . Understanding brain dysfunction in sepsis. Ann Intensive Care. 2013; 3(1):15. PMC: 3673822. DOI: 10.1186/2110-5820-3-15. View

Szulcek R, Bogaard H, van Nieuw Amerongen G . Electric cell-substrate impedance sensing for the quantification of endothelial proliferation, barrier function, and motility. J Vis Exp. 2014; (85). PMC: 4159052. DOI: 10.3791/51300. View

Liu L, Duff K . A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp. 2008; (21). PMC: 2762909. DOI: 10.3791/960. View

Vandenbroucke R, Dejonckheere E, Van Lint P, Demeestere D, Van Wonterghem E, Vanlaere I . Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J Neurosci. 2012; 32(29):9805-16. PMC: 6621276. DOI: 10.1523/JNEUROSCI.0967-12.2012. View

Maitra S, Jacob A, Zhou M, Wang P . Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int J Clin Exp Med. 2010; 3(3):180-5. PMC: 2929943. View

10.

Park H, Jin Y, Hurst D, Monroe C, Lee S, Schwartz M . The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J Biol Chem. 2003; 278(51):51646-53. DOI: 10.1074/jbc.M310109200. View

11.

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

12.

Solan P, Dunsmore K, Denenberg A, Odoms K, Zingarelli B, Wong H . A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med. 2011; 40(2):379-87. PMC: 3261337. DOI: 10.1097/CCM.0b013e318232e404. View

13.

Tressel S, Kaneider N, Kasuda S, Foley C, Koukos G, Austin K . A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011; 3(7):370-84. PMC: 3394510. DOI: 10.1002/emmm.201100145. View

14.

Lauhio A, Hastbacka J, Pettila V, Tervahartiala T, Karlsson S, Varpula T . Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res. 2011; 64(6):590-4. DOI: 10.1016/j.phrs.2011.06.019. View

15.

Puerta D, Griffin M, Lewis J, Romero-Perez D, Garcia R, Villarreal F . Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem. 2006; 11(2):131-8. DOI: 10.1007/s00775-005-0053-x. View

16.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

17.

Vandenbroucke R, Vanlaere I, Van Hauwermeiren F, Van Wonterghem E, Wilson C, Libert C . Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. Mucosal Immunol. 2013; 7(3):579-88. DOI: 10.1038/mi.2013.76. View

18.

Vandenbroucke R, Dejonckheere E, Van Hauwermeiren F, Lodens S, De Rycke R, Van Wonterghem E . Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013; 5(7):1000-16. PMC: 3721470. DOI: 10.1002/emmm.201202100. View

19.

Ethell I, Ethell D . Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 2007; 85(13):2813-23. DOI: 10.1002/jnr.21273. View

20.

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View